PROCEPT BioRobotics (PRCT) said Monday that an independent trial showed its aquablation therapy provided similar symptom relief, with superior ejaculatory function and continence preservation compared to laser enucleation for treating large prostates.
The company said the study, which treated 186 men, showed positive results for the three-month primary safety and efficacy endpoints, with long-term follow-up planned for up to five years.
The aquablation therapy arm also reported a 0% transfusion rate, highlighting the therapy's safety and effectiveness in minimizing bleeding risks, it added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。